In-depth coverage of the latest AI & GPU Accelerators developments, trends, and analysis — curated daily.
NVIDIA's shoving Google's Gemma 4 models onto everything from Jetson bots to your RTX rig. Promises low-latency magic — but who's really cashing in on this edge AI push?
NVIDIA's cracking open Omniverse with libraries that let you bolt on physical AI without swallowing the whole stack. Smart move—or sly retention play?
Picture this: 8,000 GPUs humming in unison on Kubernetes, jobs queued by trusty old Slurm. NVIDIA's not ditching their HPC roots—they're supercharging them.
Intel's latest MLPerf Inference v6.0 scores have the Arc Pro B70 flexing 1.8x faster than its predecessor. Progress, sure — but in Nvidia's world, is this a win or just catching up?
NVIDIA's platform just swept MLPerf Inference v6.0, claiming the lowest token costs ever. But after 20 years watching Valley hype, I'm asking: who's actually banking the profits here?
Data scientists drown in terabytes while CPUs choke. NVIDIA's RTX PRO 6000 Blackwell Workstation Edition claims to fix that with data-center muscle at desk level — but supply woes and real-world fit raise questions.
NVIDIA's Gemma 4 tweaks promise blazing local AI without cloud crutches. But does it deliver on agentic hype?
Forget wrestling with app stores and device builds. NVIDIA's CloudXR.js hands enterprise XR to any web dev with a URL, potentially exploding adoption in training and digital twins.
AlphaFold2 unlocked 200 million monomer structures. But protein complexes? NVIDIA's GPU blitz just predicted millions more — if you can afford the SuperPOD.
Full GPU blaze. No more idle spins. NVIDIA's batching VC-6 to blitz vision AI pipelines—but does it seal the data-to-tensor gap for real?
1,000,000x. That's how much NVIDIA claims its chips have boosted inference throughput per megawatt across six generations. Impressive—if it holds up outside the demo reels.
NVIDIA just dropped Proteina-Complexa, an AI that spits out ready-to-test protein binders for tough disease targets. Labs from Duke to Novo Nordisk are already validating its designs—proof that GPU muscle is invading drug discovery.